US University is undertaking a Study of Beta-Blocker Use in Patients With COPD and Acute MI
Photo by Ibrahim Boran
The University of Minnesota is enrolling patients into the clinical trial investigating An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI.
The study of patients admitted to the BLOCK COPD network hospitals with acute AMI and COPD to determine the prevalence of COPD in patients admitted to the hospital with an acute myocardial infarction (AMI) and to characterize the phenotypic expression and severity of their underlying lung disease. Patients with will be identified via the EMR.
Among study population are patients hospitalized and who undergo cardiac catheterization with AMI and have EMR-documented COPD.
The inclusion parameters are:
- Men and women age 35 or older.
- Admitted to hospital from the Emergency Department or by hospital to hospital transfer with a primary diagnosis of AMI.
- Undergo cardiac catheterization for AMI
- EMR-documented COPD.
Among the exclusion criteria are:
- Cognitive disorder that in the judgment of the investigator impairs understanding of the study objectives or assessments.
- Vulnerable populations, including prisoners and pregnant women.
The studies will be conducted in the following American cities: Birmingham, Alabama, Fresno, California, Los Angeles, California, San Francisco, California, Denver, Colorado, Gainesville, Florida, Chicago, Illinois, New Orleans, Louisiana, Baltimore, Maryland, Ann Arbor, Michigan, Minneapolis, Minnesota, Minneapolis, Minnesota, Rochester, Minnesota, Brooklyn, New York, Flushing, New York, New York, New York, Cincinnati, Ohio, Cleveland, Ohio, Philadelphia, Pennsylvania, Pittsburgh, Pennsylvania, Salt Lake City, Utah, Burlington, Vermont and Spokane, Washington.
University of Minnesota,United States Department of Defense and University of Alabama at Birmingham are the collaborators in this clinical trial.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04717492
